TW202321204A - 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用 - Google Patents

靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用 Download PDF

Info

Publication number
TW202321204A
TW202321204A TW111142867A TW111142867A TW202321204A TW 202321204 A TW202321204 A TW 202321204A TW 111142867 A TW111142867 A TW 111142867A TW 111142867 A TW111142867 A TW 111142867A TW 202321204 A TW202321204 A TW 202321204A
Authority
TW
Taiwan
Prior art keywords
psma
ligand compound
integer
pharmaceutically acceptable
ester
Prior art date
Application number
TW111142867A
Other languages
English (en)
Chinese (zh)
Inventor
鐘誌遠
袁建棟
楊江濤
皇甫貞元
孫娟
徐斌
陶蕾
Original Assignee
大陸商蘇州瑞核醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商蘇州瑞核醫藥科技有限公司 filed Critical 大陸商蘇州瑞核醫藥科技有限公司
Publication of TW202321204A publication Critical patent/TW202321204A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111142867A 2021-11-10 2022-11-09 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用 TW202321204A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111329108.1 2021-11-10
CN202111329108 2021-11-10

Publications (1)

Publication Number Publication Date
TW202321204A true TW202321204A (zh) 2023-06-01

Family

ID=86335105

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142867A TW202321204A (zh) 2021-11-10 2022-11-09 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用

Country Status (9)

Country Link
US (1) US20260069725A1 (https=)
EP (1) EP4431503A1 (https=)
JP (1) JP2024544870A (https=)
KR (1) KR20240105380A (https=)
CN (1) CN118176188A (https=)
AU (1) AU2022384375A1 (https=)
CA (1) CA3237743A1 (https=)
TW (1) TW202321204A (https=)
WO (1) WO2023083209A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN117069670B (zh) * 2023-07-31 2026-04-10 复旦大学附属华山医院 靶向psma的二聚体化合物及其衍生物和应用
CN119954773A (zh) * 2023-10-31 2025-05-09 苏州威智创科生物有限公司 Psma化合物、包含其的药物组合物及其用途
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
CN118221764A (zh) * 2024-03-05 2024-06-21 苏州大学 一种双靶向分子探针及其制备方法与应用
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629201B2 (en) * 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物

Also Published As

Publication number Publication date
JP2024544870A (ja) 2024-12-05
AU2022384375A1 (en) 2024-05-09
CN118176188A (zh) 2024-06-11
KR20240105380A (ko) 2024-07-05
EP4431503A1 (en) 2024-09-18
CA3237743A1 (en) 2023-05-19
US20260069725A1 (en) 2026-03-12
WO2023083209A1 (zh) 2023-05-19

Similar Documents

Publication Publication Date Title
TW202321204A (zh) 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用
EP3524277B1 (en) Psma-targeting compound and uses thereof
CN102911256B (zh) 一种放射性标记的多肽配合物及其制备方法和应用
CN118955478B (zh) 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
CN116514735B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
CN115745903B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
CN114773433A (zh) 一种cd25靶向多肽、分子探针及应用
CN112043839A (zh) 靶向转铁蛋白受体的放射性同位素标记多肽显像剂及其应用
TWI893724B (zh) 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN107308466B (zh) 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用
JP2000507233A (ja) 新規の三元複合体放射性薬剤
CN118388598A (zh) 标记前体、探针及其制备方法和应用
CN107674117B (zh) Cu-64 标记的Dimer-San A环肽衍生物胰腺癌分子探针的制备方法
CN116763946B (zh) 用于pd-l1靶向的环状多肽放射性药物及其制备方法和用途
CN118307640B (zh) 一种pet显像剂前体、pet显像剂及其制备方法和应用
CN105884646B (zh) 一种锝‑99m标记的美法仑配合物及其制备方法与用途
WO2025153101A1 (zh) 一种含氮化合物及其制备方法与用途
CN118725026A (zh) 一类靶向肿瘤相关成纤维细胞激活蛋白的糖肽、放射性核素标记物及其应用
CN119751415A (zh) 双靶向PSMA和FAP-α的前列腺癌诊断或治疗放射性药物
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤